Effect of Caffeine on Endurance Performance in Athletes May Depend on HTR2A and CYP1A2 Genotypes

J Strength Cond Res. 2022 Sep 1;36(9):2486-2492. doi: 10.1519/JSC.0000000000003665. Epub 2020 Jun 17.

Abstract

Guest, NS, Corey, P, Tyrrell, PN, and El-Sohemy, A. Effect of caffeine on endurance performance in athletes may depend on HTR2A and CYP1A2 genotypes. J Strength Cond Res 36(9): 2486-2492, 2022-This investigation determined whether variation in the HTR2A (serotonin receptor) gene modifies the ergogenic effects of caffeine on endurance and further modifies performance by the CYP1A2 genotype. Male athletes ( n = 100; 25 ± 4 years) completed 10-km cycling time trials under 3 conditions as follows: 0, 2, or 4 mg of caffeine per kg body mass. Using a randomized, double-blinded, placebo-controlled design, data were analyzed using analysis of covariance to compare changes in cycling time between placebo (0 mg·kg -1 ) and each caffeine dose and adjusted for the placebo trial and order of treatment. A significance of ρ ≤ 0.05 was used. Subjects were genotyped for HTR2A (rs6313) and CYP1A2 (rs762551). A significant caffeine- HTR2A interaction ( p = 0.003) was observed; however, after adjustment for placebo trials, the interaction was no longer significant ( p = 0.37). Because of the strong caffeine- CYP1A2 interaction ( p < 0.0001) previously reported in these subjects, where the 4-mg dose resulted in divergent effects (slower and faster) on the 10-km cycling time, we conducted a simplified model to examine these same factors by the HTR2A genotype. The post hoc analysis excluded HTR2A CT heterozygotes and 2-mg·kg -1 caffeine trials. Among CYP1A2 fast metabolizers alone, a significant difference (1.7 minutes; p = 0.006) was observed when comparing (4- vs. 0-mg·kg -1 caffeine trials) between the HTR2A CC ( n = 16; 2.4 minutes) and TT ( n = 7; 0.7 minutes) genotypes. Our results show that 4-mg·kg -1 caffeine improves performance in individuals with the HTR2A CC genotype but only in those who are also CYP1A2 AA fast metabolizers. This study was registered with clinicaltrials.gov (NCT02109783).

Trial registration: ClinicalTrials.gov NCT00210978 NCT02109783 NCT00210978.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Athletes*
  • Caffeine* / pharmacology
  • Cytochrome P-450 CYP1A2* / genetics
  • Double-Blind Method
  • Genotype
  • Humans
  • Male
  • Performance-Enhancing Substances* / pharmacology
  • Receptor, Serotonin, 5-HT2A* / genetics

Substances

  • HTR2A protein, human
  • Performance-Enhancing Substances
  • Receptor, Serotonin, 5-HT2A
  • Caffeine
  • CYP1A2 protein, human
  • Cytochrome P-450 CYP1A2

Associated data

  • ClinicalTrials.gov/NCT00210978
  • ClinicalTrials.gov/NCT02109783
  • ClinicalTrials.gov/NCT00210978